Windtree Therapeutics (WINT) announced that istaroxime was chosen for a presentation entitled, “Safety and Efficacy of intravenous administration of istaroxime for 48 hours in patients with SCAI Stage C cardiogenic shock due to heart failure” at the Heart Failure Society of America, HFSA, Annual Scientific Meeting 2025. “We are very pleased with the interim results of the SEISMiC C study,” said Jed Latkin, Chief Executive Officer of Windtree. “We believe istaroxime can be an important drug innovation for acute decompensated heart failure and cardiogenic shock patients because the istaroxime studies have promising results and this is a condition with a large unmet need and has been underserved for decades.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree Therapeutics Terminates SEISMiC-C Clinical Study
- Windtree Therapeutics Reveals Promising Phase 2 Study Data
- Windtree announces results of interim analysis of SEISMiC Phase 2 study
- Windtree Therapeutics Appoints New Audit Committee Chair
- Windtree Therapeutics announces reduction of Preferred Series C, D shares